NCT00955760已完成1 期
A Single Center, Open-Label, Three Periods, Fixed Sequence Design Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
Primary Objectives:
• Assess the effects of poly-specific cytochrome P450 and drug-transporter induction by repeated dose Rifampicin (600 mg/day) co-administration on the single-dose pharmacokinetics of Neramexane.
Secondary Objectives:
• To assess safety and tolerability of Neramexane single dose treatment alone and co-administration of a Neramexane single dose with a Rifampicin repeated dose treatment.
研究设计
- 研究类型
- Interventional
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult subject, who is able to read, to write and fully understand German language
- •Aged 18 to 45 years (inclusive)
- •BMI of 18-28 kg/m2 (inclusive) and a body weight of 50-90 kg (inclusive)
- •Willing and able to provide written informed consent after having been informed of the requirements and the restrictions of the study
- •Female subjects of childbearing potential must agree to use a highly effective method of birth control defined as those which result in a low failure rate (i.e., less than 1 % per year) when used consistently and correctly such as sexual abstinence, vasectomised partner, non hormonal IUDs, double barrier methods, e.g., condom and spermicide cream
排除标准
- •Safety concerns
- •History of clinically relevant allergy or known hypersensitivity to Neramexane/Memantine/Amantadine and their derivatives
- •History of clinically relevant allergy or known hypersensitivity to Rifampicin or other rifamycines
- •History of clinically relevant allergy or known hypersensitivity to any inactive ingredient in any of the used investigational products or the metabolic inducer
- •Exposure to another investigational agent within the last two months before Day 1 of Period 1
- •Lactating or pregnant females or females planning to become pregnant during study conduct or within 2 months after end of study. Males planning to beget children during study conduct or within 2 months after end of study
- •Any contraindications which are indicated in the topically valid SPC for EREMFAT®: severe hepatic impairment like obstructive jaundice, hepatitis, hepatic cirrhosis
- •Lack of suitability for the trial
- •Any evidence of a significant cardiovascular, pulmonary, renal, hepatic, gastrointestinal, endocrinological, metabolic or other disease at screening
- •History of malignancy
- •Any clinically relevant deviation in clinical or laboratory assessment
- •ECG abnormalities of clinical relevance, in particular abnormal prolongations of QT/QTc-interval (i.e., QTc ≥ 450 ms, PQ ≥ 220 ms)
- •Systolic blood pressure < 95 mmHg or >150 mmHg or diastolic blood pressure < 50 mmHg or >90 mmHg in supine position
- •Pulse rate <45 or >100 beats per minute
- •Chronic or acute clinically relevant infections
- •Chronic or acute disease, especially psychiatric or neurologic disorders
- •History of alcohol or drug dependence
- •Alcohol consumption averaging more than 40 g for male and more than 20 g for female subjects daily within the last year
- •Regular caffeine consumption averaging more than 1 L of coffee and/or tea daily or more than 1 L of caffeine-containing lemonades per day within the last year
- •Disorders or surgery of the gastrointestinal tract which may interfere with drug absorption or may otherwise influence the pharmacokinetics of the investigational medicinal products (e.g., cholecystectomy, ulcus, etc.)
- •Use of any prescribed medication for four weeks prior to the first administration of IMP.
- •Regular use of over-the-counter drugs [OTC] in the 4 weeks prior to the first administration of the IMP
- •Occasional use of OTC drugs (except paracetamol, maximum 1 g/day) within the 2 weeks prior to the first administration of the IMP.
- •Stable intake of thyroid hormone substitution will be allowed.
- •Use of any food, food supplement or medication known to induce or inhibit CYP3A4 or other cytochrome P450 enzymes within two weeks preceding the start of the study (Day 1), e.g. grapefruit, St. John's wort
- •Female subjects who employed any form of hormonal contraception within 2 months prior to study Day 1 (e.g. oral contraceptives, hormone releasing intrauterine contraceptive devices [IUDs], etc.)
- •Consumption of xanthine derivates (including caffeine) within two days prior to Day 1
- •Smoker and user of snuff, nicotine replacement and chewing tobacco
- •Previous enrollment into the clinical phase of the current study
- •Positive results in any of the serology tests
- •Blood donation more than 450 mL within 60 days prior to Day 1
- •Positive pregnancy test, if female
- •Positive drug screen or alcohol test
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult ParticipantsHealthyNCT04410094Janssen Research & Development, LLC32
已完成
1 期
The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy MalesHealthyMaleNCT04470908BeiGene13
已完成
1 期
Effect of Itraconazole on the Pharmacokinetics of BIIB074Neuropathic PainNCT02698267Biogen16
已完成
1 期
A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy ParticipantsHealthy ParticipantsNCT06170723Celgene32
已完成
早期 1 期
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT05891119Amgen21